TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07011654: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 31 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07011654 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07011654 Rescue Dossier →